Shrotri, M., Krutikov, M., Nacer-Laidi, H., Azmi, B., Palmer, T., Gidding, R., et al. (2022) Duration of Vaccine Effectiveness against SARS-CoV-2 Infection, Hospitalisation, and Death in Residents and Staff of Long-Term Care Facilities in England (VIVALDI): A Prospective Cohort Study. Lancet Healthy Longevity, 3, e470-e480.
https://doi.org/10.1016/S2666-7568(22)00147-7

has been cited by the following article:

• TITLE: Waning of Anti-Spike IgG Antibody Titer after COVID-19 Vaccination: Myth or Reality?

  AUTHORS: Laurent Dupoirieux

  KEYWORDS: SARS-CoV-2, COVID-19 Vaccines, Anti-Spike IgG Antibodies

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.11 No.8, August 8, 2023

  ABSTRACT: This observational prospective study was conducted on 25 patients who had received a full 3-dose COVID-19 vaccination scheme with a follow-up ranging from 12 to 19 months after the last injection. The aim of the study was focused on a single biological indicator the anti-spike IgG antibody titer. The age of the patients ranged from 51 to 85 years old. 15 out 25 patients (60%) presented a comorbidity. Our data showed a persistent positive anti-spike IgG antibodies titer ranging from 105 to 5680 BAU/mL (mean: 2661 BAU/mL) in all patients. In view of these results, systematic administration of a SARS-CoV-2 vaccine booster is questionable and should be individually tailored according to the patient medical condition and the anti-spike IgG antibody level.